Suzhou Basecare Medical Corp. Ltd. Class H (2170) AI Stock Analysis

• Market Cap: HK$495.08M
• Dividend Yield: N/A
• Average Volume (3M): 121.73K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.34
• Revenue Growth: 11.43%
• EPS Growth: 4.88%
• Country: HK
• Employees: 497
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.45
• Shares Outstanding: 82,713,840
• 10 Day Avg. Volume: 98,950
• 30 Day Avg. Volume: 121,733
• PEG Ratio: -0.12
• Price to Book (P/B): 0.62
• Price to Sales (P/S): 2.35
• P/FCF Ratio: -2.18
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.23
• Revenue Forecast (FY): HK$412.00M

• Rating: 44 Neutral
• Price Target: HK$2.00 ▲(1.52% Upside)
• Action: Reiterated Date: 11/22/25
• Date: Action: Reiterated 11/22/25

The overall stock score of 44 reflects significant challenges in financial performance, technical analysis, and valuation. The company's strong revenue growth is overshadowed by high operating costs and leverage risks, while bearish technical indicators and a negative P/E ratio further weigh down the score. Improvement in operational efficiency and financial stability is crucial for enhancing the stock's attractiveness.

Positive Factors

Revenue Growth

Sustained ~11.4% revenue growth indicates expanding product adoption and market penetration. Over the next 2–6 months this underlying top-line momentum supports scale benefits, revenue visibility and provides a base to improve operating leverage if management tightens cost controls.

Product & R&D Diversification

A diversified portfolio across imaging, in vitro diagnostics and healthcare IT plus a stated R&D focus reduces single-product risk, enables cross-selling to hospitals and supports recurring service and maintenance revenue. This structural mix enhances resilience to demand shifts and fosters long-term competitiveness.

Balance Sheet Liquidity

A solid equity ratio and available cash/short-term investments provide a financial buffer to fund operations, cover near-term obligations and support product development while management addresses profitability. This liquidity underpins strategic flexibility over the medium term.

Negative Factors

Negative Profitability

Persistent negative net margins despite revenue growth signal structural cost issues (SG&A, R&D or scale inefficiencies). Without durable operating-cost reduction, the company will struggle to convert sales into sustainable profits and returns, limiting long-term shareholder value creation.

High Leverage

Elevated leverage raises refinancing, interest and covenant risks, particularly if cash generation remains weak. High debt constrains capital allocation, increases fixed costs and reduces resilience to shocks, making it harder to invest in R&D or absorb margin pressure over coming quarters.

Weak Cash Generation

Ongoing negative operating cash flow indicates the core business does not reliably convert revenue into cash. This structural shortfall forces reliance on external financing, limits reinvestment capacity and elevates solvency risk unless operating cash conversion materially improves.

Suzhou Basecare Medical Corp. Ltd. Class H Business Overview & Revenue Model

Company Description

Suzhou Basecare Medical Corporation Limited, an investment holding company, engages in the research, development, manufacture, and provision of genetic testing solutions for assisted reproduction and sale of genetic testing devices and instruments in the People's Republic of China. The company offers genetic test kit products, which include pre-implantation genetic test kits, such as PGT-A to detect aneuploidy; PGT-M to detect single-gene or monogenic defects in pre-implantation embryos; and PGT-SR kits to detect chromosome structural rearrangements, which are common causes of recurrent miscarriage. It also provides prenatal test kit products comprising CNV kits; postnatal test kit products consist of WES kits; and devices and instruments, including liquid nitrogen storage dewar, cryostorage system, automated workstation, sperm quality analyzer, and NGS sequencer. The company also engages in the research, development, manufacture, and sale of medical devices and instruments. In addition, it provides marketing services; and engages in the research and development of software for medical devices and instruments. The company serves hospitals and reproductive clinics. Suzhou Basecare Medical Corporation Limited was incorporated in 2010 and is headquartered in Suzhou, China.

How the Company Makes Money

Suzhou Basecare Medical Corp. Ltd. generates revenue through multiple streams, primarily by selling its medical devices and diagnostic products to hospitals, clinics, and healthcare providers. The company benefits from a diversified product portfolio, including imaging systems and diagnostic kits, which contribute significantly to its sales. Additionally, Basecare may engage in strategic partnerships with other medical technology firms or research institutions to co-develop products, thereby expanding its market reach and enhancing its revenue potential. The company's focus on research and development enables it to innovate continuously, which helps maintain a competitive edge and drives sales growth. Furthermore, Basecare may also generate income through service contracts, maintenance agreements, and training programs related to its products.

Suzhou Basecare Medical Corp. Ltd. Class H Financial Statement Overview

Summary

Suzhou Basecare Medical Corp. Ltd. exhibits robust revenue growth, driven by increased sales, however, it struggles with profitability due to high operating costs. The balance sheet indicates a sound equity base but is offset by high leverage, posing risks in financial stability. Cash flow generation remains a critical challenge, with persistent operational cash deficits undermining financial resilience. Overall, while the company shows promising growth prospects, improving operational efficiency and managing leverage are essential for enhancing financial health.

Income Statement

The company shows strong revenue growth with a consistent increase in total revenue over the years, indicating solid sales expansion. However, the net profit margin remains negative due to high operating expenses, impacting overall profitability. The gross profit margin is healthy, suggesting effective cost management in production, but the negative EBIT and EBITDA margins highlight ongoing challenges in operating efficiency.

Balance Sheet

The balance sheet reflects a stable equity base with a solid equity ratio, indicating strong capital structure. However, the high debt-to-equity ratio suggests potential leverage risk. The positive cash and short-term investments position bolsters liquidity, yet the negative net income limits return on equity, which remains a concern for investors.

Cash Flow

The cash flow statement shows consistent negative operating cash flow, raising concerns about the company's ability to generate cash from its core operations. The free cash flow position is improving, yet still negative, highlighting challenges in sustaining growth without external financing. The inability to convert operating cash flow to net income efficiently is a key area that needs attention.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	275.71M	299.11M	207.98M	140.90M	107.30M	81.11M
Gross Profit	131.54M	136.22M	91.35M	59.53M	51.15M	27.71M
EBITDA	-226.62M	-253.30M	-174.14M	-117.73M	-118.88M	-873.32M
Net Income	-238.59M	-237.03M	-191.69M	-123.16M	-143.65M	-877.05M
Balance Sheet
Total Assets	1.57B	1.67B	1.90B	1.78B	1.80B	350.30M
Cash, Cash Equivalents and Short-Term Investments	545.48M	684.63M	945.71M	1.33B	1.52B	192.32M
Total Debt	342.23M	328.42M	281.92M	75.54M	48.57M	31.47M
Total Liabilities	535.35M	527.47M	499.98M	188.33M	85.85M	68.96M
Stockholders Equity	1.03B	1.14B	1.40B	1.59B	1.72B	281.33M
Cash Flow
Free Cash Flow	-297.35M	-322.41M	-371.44M	-317.52M	-234.71M	-72.38M
Operating Cash Flow	-207.59M	-229.12M	-267.23M	-188.77M	-197.85M	-64.29M
Investing Cash Flow	-1.63M	-181.19M	-324.81M	-88.70M	-56.60M	33.53M
Financing Cash Flow	-2.45M	33.78M	190.55M	23.51M	1.60B	207.47M

Suzhou Basecare Medical Corp. Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.97
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2170, the sentiment is Negative. The current price of 1.97 is above the 20-day moving average (MA) of 1.86, above the 50-day MA of 1.97, and below the 200-day MA of 2.64, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 40.97 is Neutral, neither overbought nor oversold. The STOCH value of 30.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2170.

Suzhou Basecare Medical Corp. Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2500	53 Neutral	HK$1.06B	-1.91	-26.80%	―	-8.56%	-14.84%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
9996	48 Neutral	HK$3.82B	-14.06	-11.20%	―	29.25%	9.02%
2170	44 Neutral	HK$495.08M	-2.91	-20.60%	―	11.43%	4.88%
2235	44 Neutral	HK$3.17B	-495.98	-1.39%	―	49.86%	80.35%
2160	43 Neutral	HK$4.11B	-218.71	0.22%	―	-4.38%	―
2216	41 Neutral	HK$787.82M	-4.03	-8.93%	―	-30.60%	28.61%

Suzhou Basecare Medical Corp. Ltd. Class H Corporate Events

Suzhou Basecare Non-Executive Director Ling Yang Resigns

Suzhou Basecare Medical Corporation Limited has announced the resignation of non-executive director Ling Yang, effective 15 January 2026, citing personal work arrangements. The board confirmed that his departure will not reduce the number of directors below the statutory minimum, and that Ling has no disagreement with the board nor any issues requiring disclosure to the stock exchange or shareholders, suggesting limited governance disruption and continuity in the company’s board oversight.

The most recent analyst rating on (HK:2170) stock is a Sell with a HK$2.00 price target. To see the full list of analyst forecasts on Suzhou Basecare Medical Corp. Ltd. Class H stock, see the HK:2170 Stock Forecast page.

Suzhou Basecare Medical Sets Out Board and Committee Structure

Suzhou Basecare Medical Corporation Limited has announced the composition of its board of directors, led by chairman and executive director Dr. Liang Bo, alongside two other executive directors, two non-executive directors and three independent non-executive directors. The company has also detailed the membership of its three key board committees—Audit Committee, Remuneration and Appraisal Committee, and Nomination Committee—with independent directors taking chair roles in the Audit and Remuneration and Appraisal Committees, and the chairman of the board leading the Nomination Committee, underscoring an emphasis on corporate governance, oversight and compliance for its stakeholders.

The most recent analyst rating on (HK:2170) stock is a Sell with a HK$2.00 price target. To see the full list of analyst forecasts on Suzhou Basecare Medical Corp. Ltd. Class H stock, see the HK:2170 Stock Forecast page.